Simon Delmotte 
Dr Marie-Edith Bonneterre has been appointed Chief Medical Officer (CMO) at Hemerion on September 19, 2023, to steer the medical and clinical strategy of our innovative therapeutic solutions. A specialist in cancer treatment Trained as a medical oncologist, Marie-Edith Bonneterre quickly acquired solid experience in innovative cancer treatments, with her leadership of clinical trials at …
Hemerion is taking part for the first time in Deeptech Connect, an event organized by the SATTs (Tech Transfer Acceleration Companies), which brings together 100 start-ups created from disruptive technologies developed by French academic research. Created as part of the French “Investing in the Future” program, the SATTs ( Tech Transfer Acceleration Companies) finance the …
On Tuesday September 26th, Hemerion welcomed Guillaume Pépy, President of Initiative France, at the head of a delegation made up of representatives of the Initiative France network and its partners, specialists in the creation of innovative companies.This was an opportunity to highlight the clinical progress made by our team in the treatment of glioblastoma and …
Hemerion’s technology is cited as an example of a major trend in healthcare innovation in StartUs Insights’ 2023 report. Since 2014, StartUs Insights has analyzed the evolution of nearly 4 million startups across all technology sectors. The company has developed several artificial intelligence tools to detect emerging technology trends and identify the most promising startups. …
Hemerion’s teams have taken the first step towards setting up a new clinical trial in the USA, with the shipment of a complete batch of Heliance® devices and its drug Pentalafen® for the treatment of glioblastoma patients. At the end of July, Hemerion’s teams shipped to the University of Pittsburgh Medical Center all the elements …
Hemerion has received clearance from the US Food and Drug Administration (FDA) for the investigational new drug application (IND) for its Pentalafen® / Heliance® drug-device combination product for the treatment of glioblastoma (GBM). The decision enables Hemerion to proceed with a Phase I/II clinical study at University of Pittsburgh Medical Center (UPMC) by Q4 2023. …
After 9 months of intense development, the Hemerion teams met on June 5 and 6 for a series of workshops to reflect on the future of the company and its technologies for cancer treatment. In particular, Hemerion’s teams worked on the organization of the company, which has experienced strong growth over the past 12 months, …
On April 25 and 26, Maximilien Vermandel took part in Innovation Summit Dublin, an international conference organized by Medtech Strategists and attended by a large number of medical device experts and professionals. Innovation Summit Dublin is one of the largest conferences focusing on financing and partnership development in the medtech sector. Hemerion was one of …
Glioblastoma is one of the most common and severe brain cancers. It affects more than 25,000 patients per year in Europe and the United States.The technology developed by Hemerion for the treatment of this pathology, which is the result of more than 10 years of research by INSERM, the Lille University Hospital and the University …
Already awarded the Galien MedStartup prize, the innovation trophy of the Hauts-de-France region and winner of the Bpifrance i-Lab competition, Hemerion Therapeutics won on March 15, 2023 the “Coup de coeur du Public” prize at the 2nd edition of the Healthtech 2023 Trophies organized by France Biotech, in the presence of Mr. Roland Lescure, the …